Radretumab

Drug Profile

Radretumab

Alternative Names: 131 I-L19-small immunoprotein; 131I-L19-SIP; I-131-L19-SIP; I-L19-SIP; L19-131 I; L19-I131; L19-SIP

Latest Information Update: 07 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Philogen
  • Class Antineoplastics; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Haematological malignancies; Hodgkin's disease
  • No development reported Brain cancer; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 25 Jun 2015 Phase-II development is ongoing for Hematological malignancies (Hodgkin's lymphoma) in the EU (monotherapy)
  • 01 Jun 2013 Philogen completes a phase II trial in Brain cancer (combination therapy, metastatic disease) in EU (IV) (NCT01125085)
  • 25 Oct 2012 Philogen terminates a phase I trial in Non-small cell lung cancer (combination therapy, inoperable/unresectable)in Italy (NCT01124812)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top